[Budgetary impact of pneumococcal conjugate vaccination of newborns].
Pneumococcal (Pnc) disease represents a major healthcare concern being associated with severe complications. Scope of this study was to evaluate the budgetary impact effect of providing vaccination with seven-valent pneumococcal conjugate vaccine (PCV) to newborns in Lombardy (Italy). Budget impact analysis was applied to the 2004 cohort of newborns of Lombardy: efficacy data as number of pneumonia and acute otitis media (AOM) cases, and consumption of resources were derived from a large multicenter single-blind clinical study (results published) of vaccinated versus unvaccinated Italian children. Vaccinated children were administered 3 doses of PCV at 3, 5 and 11 months of age; Pnc morbidity was recorded until the 30th month of age. Economic analysis was performed in the perspective of the third party payer considering direct costs (vaccine doses, administration costs, drugs, visits and hospitalisations for management of Pnc disease complications); unit cost of resources (2006 values) was retrieved from national reimbursement tariff lists and other published sources. Our analysis suggests that the use of PCV in infants is likely to be economically justified due to savings from pneumonia and AOM cases averted, in the population of newborns of Lombardy.
Facoltà di Farmacia, Università degli Studi di Padova e pbe consulting, Verona. patrizia.berto@pbe.it
P
P
Berto
D
D
Gallio
N
N
Principi
D002017:Budgets; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007231:Infant, Newborn; D022401:Meningococcal Vaccines / Q000191:economics*; D022242:Pneumococcal Vaccines / Q000191:economics*; D012189:Retrospective Studies; D018074:Vaccines, Conjugate / Q000191:economics*
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate